CytoSorbents Announces Virtual Annual Meeting
May 27, 2020CytoSorb® is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery
May 12, 2020CytoSorbents Reports First Quarter 2020 Financial and Operational Results
May 5, 2020CytoSorbents Promotes Vincent J. Capponi to President
May 4, 2020
CytoSorbents Receives $1.1 Million in Non-Dilutive Funding from the New Jersey Business Tax Certificate Transfer Program
April 29, 2020CytoSorbents to Report Q1 2020 Operating and Financial Results
April 28, 2020Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer
April 27, 2020Development Update: U.S. FDA Grants Breakthrough Designation to CytoSorb for Removal of Ticagrelor During Cardiopulmonary Bypass in Emergent and Urgent Cardiothoracic Surgery
April 20, 2020New Study Suggests CytoSorb Improves Clinical Outcomes in Pneumonia Patients With Septic Shock and Acute Respiratory Distress Syndrome (ARDS) on ECMO
April 15, 2020U.S. FDA Grants CytoSorb® Emergency Use Authorization for Use in Patients with COVID-19 Infection
April 13, 2020CytoSorbents CEO to Discuss COVID-19 Pandemic and its CytoSorb® Treatment of Cytokine Storm in Cowen COVID-19 Series Conference Call Today
April 3, 2020
CytoSorb® Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care
March 31, 2020CytoSorb® Used to Treat More than 70 Critically-Ill COVID-19 Patients and Specifically Added to Coronavirus Treatment Guidelines in Italy and Panama
March 25, 2020CytoSorbents Provides Update on CytoSorb and COVID-19 Coronavirus Activities
March 12, 2020CytoSorbents Announces 2019 Financial and Operational Results
March 5, 2020CytoSorbents Highlights Recent Publication Using CytoSorb during Cardiac Surgery for Infective Endocarditits
March 2, 2020
CytoSorbents Enters Agreement with China Medical System Holdings Limited to Bring CytoSorb to Mainland China to Treat Critically-ill Patients with COVID-19 Coronavirus Infection
February 19, 2020CytoSorb Used Successfully to Help Treat Grade 4 Cytokine Release Syndrome Following CAR T-cell Immunotherapy in First Published Case Report
February 5, 2020
CytoSorb® is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.
January 29, 2020CytoSorb, the Wuhan Coronavirus, and Cytokine Storm
January 28, 2020CytoSorb Treatment Improves Rat Survival Following Lethal Intravenous Dose of Fungal Aflatoxin
January 22, 2020CytoSorbents Reports Preliminary 2019 Financial Results and Issues Stockholder Letter
January 14, 2020CytoSorbents to Present at Biotech Showcase™ 2020
January 7, 2020
CytoSorbents Changes Contract Research Organizations and Temporarily Pauses Enrollment in REFRESH 2-AKI Study
November 25, 2019CytoSorbents to Present at the Three Part Advisors 2019 Southwest IDEAS Investor Conference
November 19, 2019Dr. Eric Mortensen to Leave CytoSorbents At Year End
November 6, 2019CytoSorbents Reports Third Quarter 2019 Financial Results
November 5, 2019CytoSorbents Announces Additions to its International Clinical Team
November 4, 2019CytoSorbents Enrolls First Patient in TISORB Trial and Opens Operating Subsidiary in the United Kingdom
November 1, 2019
CytoSorbents to Report Q3 2019 Operating and Financial Results
October 30, 2019CytoSorbents Awarded Approximately $3.0 Million by the U.S. Air Force to Advance Development of the K+ontrol System to Treat Severe Hyperkalemia
October 22, 2019CytoSorbents to Present at The MicroCap Rodeo Investor Conference
October 10, 2019CytoSorb® Removal of Ticagrelor Intraoperatively Results in Projected Cost Savings of Approximately $5,000 in Each Patient Undergoing Emergency Cardiac Surgery
October 4, 2019CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery
October 2, 2019
CytoSorbents Highlights Survival Benefit of CytoSorb Therapy in Septic Shock
September 25, 2019First Study to Evaluate CytoSorb in Cytokine Release Syndrome (CRS) Following CAR T-cell Immunotherapy to Commence
September 16, 2019World Sepsis Day 2019: CytoSorbents Highlights Its Support of Multiple Organizations In the Fight Against Sepsis
September 13, 2019CytoSorbents to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 9, 2019
CytoSorbents Highlights Recent Published Studies on CytoSorb
August 28, 2019CytoSorbents Receives Renewal of CytoSorb® CE Mark Through May 2024 and Annual ISO 13485:2016 Certification Through September 2022
August 15, 2019CytoSorbents Expands CytoSorb Distribution in Latin America to Brazil, Colombia, and Costa Rica
August 13, 2019CytoSorbents Reports Record Second Quarter 2019 Financial Results
August 6, 2019CytoSorbents Announces Amendment to Loan Agreement with Bridge Bank, Receives an Additional $5 Million Cash from New Term Loan
August 5, 2019
CytoSorbents to Report Fiscal 2018 Operating and Financial Results
February 28, 2019CytoSorbents to Participate at the 8th Annual SVB Leerink Global Healthcare Conference
February 25, 2019CytoSorbents to Present at the 21st Annual BIO CEO & Investor Conference
February 5, 2019CytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial
February 4, 2019
CytoSorbents to Present at the 30th Annual Piper Jaffray Healthcare Conference
November 26, 2018CytoSorbents Recognized Again as One of the Fastest Growing Companies in North America on Deloitte’s 2018 Technology Fast 500™
November 19, 2018CytoSorbents to Present at the Stifel, Jefferies, and Canaccord Investor Conferences This Week
November 12, 2018CytoSorbents Reports Third Quarter 2018 Financial Results
November 6, 2018
CytoSorb® Assigned Dedicated Procedure Code in Switzerland
September 20, 2018World Sepsis Day 2018: CytoSorbents Sponsors the Sepsis Heroes Gala and the Roger Bone Award for Excellence in Sepsis Research
September 13, 2018CytoSorbents REFRESH 2-AKI Protocol Amendment Approved by FDA
September 4, 2018
CytoSorbents to Present at the B. Riley FBR Healthcare Conference and the H.C. Wainwright 20th Annual Global Investment Conference
August 28, 2018CytoSorbents Awarded up to $3M in SBIR Phase IIB Bridge Funding by NIH/NHLBI to Accelerate U.S. Approval and Commercialization of the HemoDefend™ Blood Transfusion Filter
August 21, 2018CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018
August 2, 2018
CytoSorbents Expands Distribution of CytoSorb® to a Total of 53 Countries Worldwide
July 31, 2018CytoSorbents to Report Q2 2018 Operating and Financial Results
July 26, 2018Aferetica and CytoSorbents Debut the PerLife™ System for Organ Preservation and Rehabilitation at the 27th International Congress of the Transplantation Society
July 9, 2018
CytoSorbents to Present at the 19th Annual B. Riley FBR Investor Conference
May 21, 2018CytoSorb® Adds Bilirubin and Myoglobin Reduction to European Union Approved Indications for Use
May 14, 2018CytoSorbents Reports Strong First Quarter 2018 Financial Results
May 8, 2018CytoSorbents to Report Q1 2018 Operating and Financial Results
May 2, 2018
CytoSorbents Enrolls First Patient into Pivotal U.S. REFRESH 2-AKI Trial Using CytoSorb® During Complex Cardiac Surgery
April 24, 2018CytoSorbents to Meet With European Investors at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo and in Meetings in Frankfurt, Geneva and Zurich
April 9, 2018CytoSorbents Refinances Existing Debt with New $15 Million Debt Facility with Bridge Bank
April 4, 2018
CytoSorbents Reports on the Successful 5th International CytoSorb Users Meeting and 38th ISICEM Critical Care Conference
March 28, 2018CytoSorbents to Present at the 38th Annual Cowen Healthcare Conference
March 12, 2018CytoSorbents Achieves Record Revenue and Product Sales Growth in 2017
March 8, 2018CytoSorbents to Report Fiscal 2017 Operating and Financial Results
March 1, 2018
CytoSorbents to Participate at the BTIG Healthcare Conference
February 26, 2018CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia
February 15, 2018CytoSorbents to Present at the 20th Annual BIO CEO & Investor Conference
February 6, 2018New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative CytoSorb® Blood Purification
February 1, 2018
CytoSorbents Achieves Key Milestone with FDA Approval of the U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE Application
December 21, 2017CytoSorbents Receives $676,739 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
December 19, 2017German Federal Ministry of Education and Research to Fund the CytoSorb® Endocarditis REMOVE Trial
December 11, 2017
CytoSorbents to Present at the LD Micro Main Event Investor Conference 2017
November 29, 2017CytoSorbents Continues Strong Trajectory of Growth in the Third Quarter 2017
November 9, 2017CytoSorbents Recognized on Deloitte’s 2017 Technology Fast 500™ as One of the Fastest Growing Companies in North America
CytoSorbents to Report Q3 2017 Operating and Financial Results
November 2, 2017CytoSorbents Awarded Approximately $1.0 Million in Phase II SBIR Funding to Optimize New Treatment Approaches for Severe Hyperkalemia
November 1, 2017
CytoSorbents Introduces the CytoSorb Therapeutic ECMO™ Kit at the 2017 European Society of Intensive Care Medicine Congress
September 26, 2017Key Clinical Study Showing Reversal of Refractory Septic Shock in Patients Treated with CytoSorb®
September 25, 2017World Sepsis Day 2017: CytoSorbents Sponsors the Sepsis Update 2017 Congress and Sepsis Heroes Ceremony
September 14, 2017Aferetica and CytoSorbents Partner to Enhance the Success of Solid Organ Transplantation
September 11, 2017CytoSorbents to Present at the 2017 Rodman & Renshaw Annual Global Investment Conference
September 6, 2017CytoSorbents Highlights Important Research Advances in Traumatic Brain Injury, Hemorrhagic Shock, and Severe Hyperkalemia at the Military Health System Research Symposium
September 5, 2017
CytoSorbents Expands Distribution and Sales of CytoSorb® to treat Deadly Inflammation in Panama with DRGR
July 17, 2017CytoSorbents Awarded $1 Million STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma
July 13, 2017CytoSorbents Receives Additional $5 Million in Non-Dilutive Debt Financing from Bridge Bank
July 5, 2017
Dr. Eric R. Mortensen, M.D., Ph.D., Clinical Trial Veteran, Joins CytoSorbents as Chief Medical Officer
May 30, 2017CytoSorbents Selected to Present at Special Operations SOMSA 2017 Conference and 18th Annual B. Riley & Co. Investor Conference
May 24, 2017Aferetica and CytoSorbents Extend Exclusive “Life-saving” Partnership through 2021
May 22, 2017CytoSorbents Reports First Quarter 2017 Financial Results
May 8, 2017CytoSorbents Announces Positive REFRESH I Trial Results
May 5, 2017CytoSorbents to Report Q1 2017 Operating and Financial Results
May 2, 2017
CytoSorbents Announces Pricing of Follow-On Offering
March 31, 2017CytoSorbents Announces Proposed Offering of Common Stock
March 30, 2017CytoSorbents Strengthens Intellectual Property Portfolio with New Patents Issued in the U.S., China, Japan, Russia, and Australia
March 28, 2017CytoSorbents REFRESH I Trial Abstract Selected for Podium Presentation at the American Association for Thoracic Surgery Centennial Conference
March 27, 2017Dr. Carl H. June, Cancer Immunotherapy Pioneer, Joins CytoSorbents Scientific Advisory Board
March 22, 2017CytoSorb® Treatment of HLH – The Parallel to Cytokine Release Syndrome in Cancer Immunotherapy
March 20, 2017CytoSorbents Announces CytoSorb® Partnership with Dr. Reddy’s Laboratories
March 16, 2017CytoSorbents Highlights Activities at the 22nd International Conference on Advances in Critical Care Nephrology
March 7, 2017CytoSorbents to Present at the Maxim Group – Haitong Securities Inaugural Healthcare Investor and Partnering Conference
March 6, 2017CytoSorbents Reports Record Quarterly and Full-Year 2016 Revenue
March 3, 2017CytoSorbents to Present at 37th Annual Cowen and Company Healthcare Conference
March 2, 2017
CytoSorbents to Report Fiscal 2016 Operating and Financial Results
February 24, 2017CytoSorbents to Present at the 19th Annual BIO CEO & Investor Conference
February 7, 2017
CytoSorbents Launches VetResQ™ for U.S. Veterinary Market
January 20, 2017CytoSorbents Pre-announces Q4 2016 and Full-Year 2016 Results
January 10, 2017Fresenius Medical Care and CytoSorbents Expand Original Partnership and Add New Co-Marketing Agreement for Worldwide CytoSorb® Markets
January 9, 2017CytoSorbents To Provide Corporate Update at Biotech Showcase 2017
January 3, 2017
CytoSorbents Announces First Sales of New CytoSorb® CPB Procedure Pack for Cardiac Surgery
December 20, 2016CytoSorbents Receives $318,551 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
December 12, 2016CytoSorb® Attains Permanent, Dedicated Reimbursement Code in Core Market of Germany Expected to Catalyze Major Increases in Adoption and Sales of CytoSorb® in Germany
December 7, 2016CytoSorbents to Present at the LD Micro Main Event Investor Conference
December 2, 2016CytoSorb® Selected for NICE MedTech Innovation Briefing in the United Kingdom
December 1, 2016
First Successful Treatment of Dengue Fever and Dengue Shock Syndrome Using CytoSorb®
November 22, 2016CytoSorbents Reports Highlights from the SepsEast 2016 Critical Care Congress
November 17, 2016Adrian Thomas Joins CytoSorbents to Drive Western European Sales
November 15, 2016CytoSorb® Q3 2016 Sales Reach Record $2.14M, Doubling From a Year Ago
November 7, 2016CytoSorbents Expands Direct Sales of CytoSorb to Belgium and Luxembourg
November 3, 2016CytoSorbents to Report Q3 2016 Operating and Financial Results
November 1, 2016
CytoSorbents Congratulates Kathleen Bloch as NJBIZ Public Company Chief Financial Officer of the Year
October 17, 2016CytoSorbents to Present at the 2016 BIO Investor Forum
October 14, 2016CytoSorbents and Foxx Medical Begin Saving Lives in Chile with CytoSorb®
October 11, 2016CytoSorbents Announces Positive Top-line Safety Data from REFRESH I Cardiac Surgery Trial
October 5, 2016International Marketing of CytoSorb® Commences at European Association for Cardio-Thoracic Surgery Conference
October 3, 2016
New CytoSorbents Website Highlights Global Growth and Innovation
September 29, 2016CytoSorbents Expands CytoSorb® into Iran with Partner Arsak
September 23, 2016CytoSorbents Sponsors Sepsis Heroes Gala in Honor of World Sepsis Day
September 15, 2016Terumo Cardiovascular Group and CytoSorbents Announce CytoSorb Cardiac Surgery Partnership
September 12, 2016CytoSorbents Advances War On Sepsis with Development of CytoSorb-XL
September 8, 2016CytoSorbents to Present at the 2016 Rodman & Renshaw Annual Global Investment Conference
September 7, 2016
CytoSorbents Achieves Fourth Consecutive Quarter of Record CytoSorb® Sales
August 9, 2016CytoSorbents Awarded $650,000 in SBIR Grant Contracts to Continue Development of Novel Hemocompatible Potassium Binding Polymers
August 8, 2016CytoSorbents to Report Q2 2016 Operating and Financial Results
August 2, 2016
Independent Data Safety Monitoring Board Recommends Continuation of CytoSorbents REFRESH I Trial
May 27, 2016CytoSorb® Achieves Final Product Registration in Russia
May 18, 2016CytoSorbents Continues Strong Growth in Q1 2016
May 9, 2016CytoSorbents Establishes Swiss Subsidiary
May 6, 2016CytoSorbents to Report Q1 2016 Operating and Financial Results
May 2, 2016
CytoSorbents Awarded $150,000 Phase I SBIR Contract for Fungal Mycotoxin Removal
March 25, 2016CytoSorbents Reports on Successful 3rd International CytoSorb® Users Meeting
March 16, 2016CytoSorbents to Host 3rd International CytoSorb® Users Meeting and ISICEM 2016 Symposium
March 14, 2016CytoSorbents Reports Record Quarterly and Full-Year 2015 Revenue
March 9, 2016CytoSorbents to Report Fiscal 2015 Operating and Financial Results
March 2, 2016
Data Presented on First CytoSorb® Investigator-Initiated Septic Shock Study
February 26, 2016CytoSorbents to Exhibit at the 45th Society of Critical Care Medicine Congress
February 18, 2016CytoSorbents Announces 26th Symposium for Intensive Medicine and Intensive Care Agenda in Bremen, Germany
February 16, 2016CytoSorbents to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference
February 4, 2016CytoSorbents Receives $325,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
February 1, 2016
CytoSorbents to Present at the 18th Annual BIO CEO & Investor Conference
January 28, 2016CytoSorbents Appoints Dr. Volker Humbert as Senior Manager of Clinical Affairs
January 21, 2016CytoSorbents 2016 – Driving Toward the Inflection Point
January 11, 2016CytoSorbents To Present at Biotech Showcase 2016
January 4, 2016
CytoSorbents Issues EAP Update
December 21, 2015CytoSorbents Expands Distribution of CytoSorb® to Vietnam
December 15, 2015CytoSorbents to Ring Opening Bell to Celebrate One Year NASDAQ Anniversary
December 9, 2015
CytoSorbents Accelerates Growth in Q3 2015
November 13, 2015CytoSorbents To Meet With Investors at Brean Capital Life Sciences Summit and Stifel 2015 Healthcare Conference
November 9, 2015CytoSorbents to Report Q3 2015 Operating and Financial Results
November 6, 2015
CytoSorbents Ready for Second International CytoSorb® Users Meeting, ESICM and EACTS Conferences
September 30, 2015World Sepsis Day 2015: CytoSorbents Sponsors the SepsisUpdate 2015 Congress, Hugo Schottmuller Prize, and Sepsis Heroes Ceremony
September 14, 2015CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference
September 2, 2015
CytoSorbents Reports Steady Growth in Q2 2015
August 13, 2015Saudi Food and Drug Authority Approves CytoSorb®
August 10, 2015CytoSorbents to Report Q2 2015 Operating and Financial Results
August 6, 2015
